Cargando…
An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis
Golimumab (Simponi(®)) is a fully human tumor necrosis factor α inhibitor (TNFi) antibody administered subcutaneously. In the European Union, golimumab is indicated for the treatment of adults with severe, active axial spondyloarthritis (axSpA), which includes both ankylosing spondylitis (AS) and no...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946857/ https://www.ncbi.nlm.nih.gov/pubmed/27468228 http://dx.doi.org/10.2147/DDDT.S91441 |